Updates in Eosinophilic Esophagitis

Purpose of review: Eosinophilic esophagitis (EoE) is an increasingly common allergic condition managed by a diverse group of practitioners including gastroenterologists, allergists, primary care, and emergency care providers. One of the major gaps in the care of patients with EoE is delay in diagnosis that is in part due to the varied presentation by age and gaps in disease awareness. Prompt recognition and referral to a gastroenterologist for consideration of esophagogastroduodenoscopy (EGD) with biopsies are necessary for diagnosis and subsequent access to directed therapies for patients with EoE. Recent findings: The recent United States Food and Drug Administration (FDA) approval of dupilumab marks a milestone in the treatment of EoE. It is the first treatment option for EoE to gain FDA approval and joins the list of effective therapies for patients with EoE, including proton pump inhibitors, topical corticosteroids, dietary eliminations, and dilations. Summary: The prompt recognition, diagnosis, and effective treatment of EoE are challenging, but the progress made over the past three decades has enhanced our ability to manage EoE. Continued refinement of current as well as innovative new diagnostic and therapeutic modalities will further help providers, patients with EoE, and their caregivers. © 2023, The Author(s), under exclusive licence to Springer Nature Switzerland AG.